Proteome Sciences (PRM.L)

Sunday

8:11 AM

ThesisThe recent strategic partnership and positive clinical trial results have improved investor sentiment, suggesting a potential turnaround in revenue growth.

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$4M	$3M	$3M
Rev. Growth	-23.1%	-14.8%	-6.3%
EPS	$-0.01	$-0.01	$-0.01
EPS Growth	+9.6%	+51.9%	-40.0%
P/E	—	—	—

★ Analysts see FY2027 revenue reaching $3M — -6.3% growth in a single year.

What’s Driving the Stock

01Recent collaboration with a major pharmaceutical company for Alzheimer's drug development could lead to significant revenue opportunities.
02Successful completion of a Phase II clinical trial for a diagnostic test could enhance market credibility and attract further partnerships.
03Increased focus on neurodegenerative diseases in public health policy may drive demand for diagnostic solutions.
04Growing demand for precision medicine in neurodegenerative diseases
05Increased investment in biotechnology and diagnostics
06Partnership announcements with pharmaceutical companies for drug development
07Progress in clinical trials for proprietary diagnostic tests
08Regulatory approvals for new diagnostic products

FY2025 Snapshot

Revenue: $4M
Rev. Growth: -23.1%
Gross Margin: -26.8%
Op. Margin: -71.0%
Net Margin: -81.5%
Net Income: $-3M
NI Growth: +10.1%
EPS: $-0.01
1Y Return: -59.5%

My Notes

"We are excited about the opportunities ahead as we align with leading pharmaceutical partners."
Moat: Proteome Sciences' proprietary technology in proteomics provides a unique competitive edge, though it faces pressure from larger…
growth - Investors looking for high-risk, high-reward opportunities in biotech and diagnostics.
High interest rates could increase financing costs for R&D and slow down investment in new projects, impacting growth potential.
Watch on earnings: Number of partnerships with pharmaceutical companies, Clinical trial success rates, Revenue growth from diagnostic tests.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $3M to $3M as recent collaboration with a major pharmaceutical company for alzheimer's drug development could lead to significant.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Writing up the research noteFirst read for a new ticker takes about 20-30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.